Clinical Trial Update: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous CD22-directed CAR T cells after prior commercial CD19-directed CAR T therapy in patients with B-cell malignancies; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Leukemia

Drugs mentioned

• CD19 CAR T cells
• CD22-CAR T Cells

Snippet

Sponsor: Stanford University | Conditions: Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING